206 related articles for article (PubMed ID: 35410687)
1. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
[TBL] [Abstract][Full Text] [Related]
2. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Rheum Dis Clin North Am; 2024 Aug; 50(3):483-518. PubMed ID: 38942581
[TBL] [Abstract][Full Text] [Related]
3. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
Oo WM; Little C; Duong V; Hunter DJ
Drug Des Devel Ther; 2021; 15():2921-2945. PubMed ID: 34262259
[TBL] [Abstract][Full Text] [Related]
4. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
[TBL] [Abstract][Full Text] [Related]
5. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).
Oo WM; Hunter DJ
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090297. PubMed ID: 35619876
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
[TBL] [Abstract][Full Text] [Related]
7. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
[TBL] [Abstract][Full Text] [Related]
8. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.
Gao J; Xia Z; Mary HB; Joseph J; Luo JN; Joshi N
Trends Pharmacol Sci; 2022 Mar; 43(3):171-187. PubMed ID: 35086691
[TBL] [Abstract][Full Text] [Related]
9. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
Eckstein F; Le Graverand MP
Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
[TBL] [Abstract][Full Text] [Related]
10. Latest insights in disease-modifying osteoarthritis drugs development.
Li S; Cao P; Chen T; Ding C
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231169839. PubMed ID: 37197024
[TBL] [Abstract][Full Text] [Related]
11. Prospects for Therapies in Osteoarthritis.
Ghouri A; Conaghan PG
Calcif Tissue Int; 2021 Sep; 109(3):339-350. PubMed ID: 32055890
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.
Oo WM; Yu SP; Daniel MS; Hunter DJ
Expert Opin Emerg Drugs; 2018 Dec; 23(4):331-347. PubMed ID: 30415584
[TBL] [Abstract][Full Text] [Related]
13. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets.
Le Graverand-Gastineau MP
Curr Drug Targets; 2010 May; 11(5):528-35. PubMed ID: 20199396
[TBL] [Abstract][Full Text] [Related]
14. Candidates for Intra-Articular Administration Therapeutics and Therapies of Osteoarthritis.
Toyoda E; Maehara M; Watanabe M; Sato M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808364
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.
Davies PS; Graham SM; MacFarlane RJ; Leonidou A; Mantalaris A; Tsiridis E
Expert Opin Investig Drugs; 2013 Apr; 22(4):423-41. PubMed ID: 23409708
[TBL] [Abstract][Full Text] [Related]
16. Osteoarthritis phenotypes and novel therapeutic targets.
Van Spil WE; Kubassova O; Boesen M; Bay-Jensen AC; Mobasheri A
Biochem Pharmacol; 2019 Jul; 165():41-48. PubMed ID: 30831073
[TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone and Experimental Osteoarthritis.
Huang K; Wu LD; Bao JP
Vitam Horm; 2018; 108():367-384. PubMed ID: 30029735
[TBL] [Abstract][Full Text] [Related]
18. Strontium ranelate, a promising disease modifying osteoarthritis drug.
Han W; Fan S; Bai X; Ding C
Expert Opin Investig Drugs; 2017 Mar; 26(3):375-380. PubMed ID: 28092725
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in intra-articular drug delivery systems for osteoarthritis therapy.
Maudens P; Jordan O; Allémann E
Drug Discov Today; 2018 Oct; 23(10):1761-1775. PubMed ID: 29792929
[TBL] [Abstract][Full Text] [Related]
20. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.
Jotanovic Z; Mihelic R; Sestan B; Dembic Z
Curr Drug Targets; 2014 Jun; 15(6):635-61. PubMed ID: 24597569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
